UK biotech Orchard Therapeutics is planning a US IPO to expand use of its Strimvelis gene therapy, and further develop its rare disease pipeline. A filing with the US Securities and Exchange Commission shows the biotech wants to raise $172.5 milli...
Original Article: UK biotech Orchard plans $172.5m US IPO to fund rare disease R&D